Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma

被引：1

作者：

Peng, Fengping ^{[1
]}

Wang, Yuan ^{[2
,3
]}

Zhao, Jiliang ^{[2
,3
]}

Liu, Hui ^{[1
]}

Liu, Zhaoyun ^{[1
]}

Ding, Kai ^{[1
]}

Zhang, Hongkai ^{[2
,3
]}

Fu, Rong ^{[1
]}

机构：

[1] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China

[2] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China

[3] Nankai Univ, Coll Life Sci, Tianjin, Peoples R China

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期

基金：

中国国家自然科学基金;

关键词：

B-cell maturation antigen; bispecific T-cell engager; gene therapy; in vivo electroporation; multiple myeloma;

D O I：

10.1111/bjh.18230

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The delivery of bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and CD3 using the gene therapy approach is a promising alternative for BsAb administration in patients with multiple myeloma (MM). In the present study, we evaluated the efficacy of this approach using a xenograft model. Tumour growth was significantly delayed in mice treated with single electroporation-enhanced intramuscular injection of plasmid DNA encoding BCMA/CD3 BsAb in contrast to the vehicle control-treated group. Limited toxicity was observed following treatment. This study demonstrates that the gene therapy-based approach for the delivery of BCMA/CD3 BsAb is effective and safe for the treatment of MM.

引用

页码：417 / 421

页数：5

共 50 条

[21] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[22] T cell-dependent bispecific antibody anti-CD79b/CD3 as a potential therapy for B-cell malignancies
Wang, Peiyin
Hristopoulos, Maria
Clark, Robyn
Chen, Yvonne
Ellerman, Diego
Mathieu, Mary
Spiess, Christoph
Li, Jessica
Chalouni, Cecile
Sukumaran, Siddharth
Stefanich, Eric
Wallin, Jeffrey
Li, Robert
Zabka, Tanja
Totpal, Klara
Dennis, Mark
Ebens, Allen
Gould, Stephen
Polson, Andrew
Sun, Liping Laura
CANCER RESEARCH, 2017, 77
[23] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Ahsan, Aarif
Mantis, Christine
Luo, Xizhi
Zhang, Catherine C.
Valdes, Cesar Rodriguez
Voorhees, Peter M.
D'Souza, Anita
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Mckay, John T.
Weisel, Katja C.
Teipel, Raphael
Korde, Neha
Vij, Ravi
Kumar, Shaji
Bueno, Orlando Felix
Pothacamury, Rajvineeth Kumar
Talati, Chetasi
Ross, Jeremy A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lesokhin, Alexander M.
Levy, Moshe Y.
Dalovisio, Andrew P.
Bahlis, Nizar J.
Solh, Melhem
Sebag, Michael
Jakubowiak, Andrzej
Jethava, Yogesh S.
Costello, Caitlin L.
Chu, Michael P.
Savona, Michael R.
Gasparetto, Cristina
Trudel, Suzanne
Chou, Jeffrey
Udata, Chandrasekhar
Basu, Cynthia
Krupka, Heike I.
Raje, Noopur S.
BLOOD, 2020, 136
[26] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, A. Eli
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur S.
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos Gabor
Viqueira, Andrea
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[27] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin, Alexander M.
Arnulf, Bertrand
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Tomasson, Michael H.
Rodriguez-Otero, Paula
Quach, Hang
Raje, Noopur S.
Iida, Shinsuke
Raab, Marc-Steffen
Czibere, Akos
Sullivan, Sharon
Leip, Eric
Viqueira, Andrea
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Raje, Noopur S.
Jakubowiak, Andrzej
Gasparetto, Cristina
Cornell, Robert F.
Krupka, Heike I.
Navarro, Daniel
Forgie, Alison J.
Udata, Chandrasekhar
Basu, Cynthia
Chou, Jeffrey
Leung, Abraham
Lesokhin, Alexander M.
BLOOD, 2019, 134
[29] A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma
Xiong, Mengshang
Liu, Ruoqi
Lei, Xiaomin
Fan, Dongmei
Lin, Fangzhen
Hao, Wei
Yuan, Xiangfei
Yang, Yuanyuan
Zhang, Xiaolong
Ye, Zhou
Lu, Yang
Zhang, Yanjun
Wang, Jianxiang
Xiong, Dongsheng
JOURNAL OF IMMUNOTHERAPY, 2022, 45 (02) : 78 - 88
[30] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels
Moreau, Philippe
Garfall, Alfred
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay
Martin, Thomas
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478

← 1 2 3 4 5 →